The estimated Net Worth of Jan M Lundberg is at least $12.2 Milhão dollars as of 1 February 2018. Jan Lundberg owns over 36,252 units of Ardelyx Inc stock worth over $1,277,198 and over the last 15 years he sold ARDX stock worth over $10,827,221. In addition, he makes $141,985 as Independent Director at Ardelyx Inc.
Jan has made over 12 trades of the Ardelyx Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 36,252 units of ARDX stock worth $216,062 on 1 February 2018.
The largest trade he's ever made was selling 121,711 units of Ardelyx Inc stock on 1 February 2015 worth over $8,614,705. On average, Jan trades about 14,172 units every 88 days since 2010. As of 1 February 2018 he still owns at least 214,295 units of Ardelyx Inc stock.
You can see the complete history of Jan Lundberg stock trades at the bottom of the page.
Dr. Jan M. Lundberg Ph.D. serves as Independent Director of the Company. Dr. Lundberg served as the President of Lilly Research Laboratories and Executive Vice President of Science and Technology for Eli Lilly and Company (NYSE: LLY) from January 2010 to March 2018. Prior to joining Lilly he served for ten years as global head of discovery research at AstraZeneca Plc (NYSE: AZN), where he was a member of the senior executive team. Dr. Lundberg also served as a professor at the Karolinska Institute’s department of pharmacology in Sweden, and was a cofounder of biotechnology company, Aerocrine. Dr. Lundberg currently serves on the board of directors of several privately held life sciences companies and non-profit organizations. Dr. Lundberg was instrumental in the establishment of the Innovative Medicines Initiative in Europe and the Accelerating Medicines Partnership with National Institutes of Health. Dr. Lundberg received a B.S.M. in medicine from the University of Gothenberg and a Ph.D. in pharmacology from the Karolinska Institute in Sweden. Lundberg is qualified to serve on our board of directors due to his extensive scientific research background and significant life science industry experience.
As the Independent Director of Ardelyx Inc, the total compensation of Jan Lundberg at Ardelyx Inc is $141,985. There are 11 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
Jan Lundberg is 66, he's been the Independent Director of Ardelyx Inc since 2018. There are 1 older and 18 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Jan's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: